Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12146427 | 0.77 | CDK8 (0.36) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24005900 | 0.76 | CDK8 (0.34) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24005526 | 0.76 | CDK8 (0.35) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24005537 | 0.76 | PIK3CA (0.37) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19367715 | 0.73 | CDK8 (0.34) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19441648 | 0.73 | FEN1 (0.36) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25650900 | 0.70 | LPAR1 (0.33) | CDK8AXLBRD4FGFR1KDR | |
| SCHEMBL19359596 | 0.69 | HPGD (0.43) | — | |
| SCHEMBL25650901 | 0.69 | CDK8 (0.44) | CDK8BRD4FGFR1KDR | |
| SCHEMBL21027640 | 0.69 | ADORA2A (0.36) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | CDK8 533/4885AXL 3563/4885PIK3CD 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.